Billiontoone - Class A (BLLN) closed at $105.15 on November 13, 2026, down 5.1% from the previous close, on volume of 603,507 shares (30-day average 570,296).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 4, 2026 | Put with Delta Hedge | 20-Nov-26 110 P +19,800 Stock | 562 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
BillionToOne Earnings Call Signals Strong Growth Ahead
TipRanks (Thu, 12-Nov 7:28 PM ET)
Norwest Announces $4 Billion Global, Multi-Stage Fund
Business Wire (Thu, 12-Nov 6:00 AM ET)
BillionToOne Reports Third Quarter 2026 Results and Raises 2026 Revenue Guidance
Globe Newswire (Wed, 4-Nov 4:05 PM ET)
BillionToOne to Participate in Two Upcoming Investor Conferences
Globe Newswire (Tue, 27-Oct 8:05 AM ET)
BillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026
Globe Newswire (Wed, 14-Oct 8:05 AM ET)
Globe Newswire (Wed, 7-Oct 7:00 AM ET)
BillionToOne to Participate in the Wells Fargo 21st Annual Healthcare Conference
PRNewswire (Wed, 2-Sep 4:06 PM ET)
BillionToOne Launches Northstar Origin, a New Liquid Biopsy Test to Help Identify Tissue of Origin
PRNewswire (Tue, 1-Sep 9:01 AM ET)
/C O R R E C T I O N -- BillionToOne/
PRNewswire (Wed, 19-Aug 10:22 AM ET)
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
Billiontoone - Class A trades on the NASDAQ stock market under the symbol BLLN.
As of November 13, 2026, BLLN stock price declined to $105.15 with 603,507 million shares trading.
BLLN has a beta of -0.26, meaning it tends to be less sensitive to market movements. BLLN has a correlation of 0.00 to the broad based SPY ETF.
BLLN has a market cap of $5.02 billion. This is considered a Mid Cap stock.
Last quarter Billiontoone - Class A reported $123 million in Revenue and $.32 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.05.
The top ETF exchange traded funds that BLLN belongs to (by Net Assets): VTI, VB, VBK, VXF, SCHA.
BLLN has outperformed the market in the last year with a return of +17.4%, while the SPY ETF gained +13.4%. In the last 3 month period, BLLN beat the market returning +11.8%, while SPY returned -2.8%. However, in the most recent 2 weeks BLLN has underperformed the stock market by returning -7.2%, while SPY returned -0.2%.
BLLN support price is $106.60 and resistance is $114.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BLLN shares will trade within this expected range on the day.
